Age at Diagnosis is an Independent Predictor of Small Renal Cell Carcinoma Recurrence-Free Survival
Purpose
Controversy exists as to the influence of age at diagnosis on prognosis in patients with renal cell carcinoma. We investigated the relationship between age at diagnosis and disease recurrence after surgery in patients with small renal cell carcinoma.
Materials and Methods
Of the 1,196 patients who underwent curative surgery for renal cell carcinoma between 1989 and 2005 at our institution 490 with renal cell carcinoma 4 cm or less were included in our study. Patients were stratified into 3 subgroups according to age at diagnosis, including 40 years or less in 93, 41 to 60 years in 253 and greater than 60 years in 144. Clinical and pathological variables at diagnosis were compared and survival analysis was performed.
Results
A total of 17 patients (3.5%) experienced disease recurrence and 9 (1.8%) died of metastatic renal cell carcinoma during followup. Higher Fuhrman nuclear grade was associated with older age at diagnosis (p = 0.001). Histological subtypes were associated with age categories (p = 0.016). The overall recurrence-free survival rate was 97.2% and 92.4% at 5 and 10 years, respectively. The 10-year recurrence-free survival rate was 100% for patients 40 years old or younger, 95.7% for those 41 to 60 years old and 79.0% for those older than 60 years (p = 0.002). Multivariate analysis revealed that age at diagnosis and Fuhrman grade independently predicted recurrence-free survival (p = 0.027 and <0.001, respectively).
Conclusions
Age at diagnosis was an independent predictor of recurrence-free survival after curative surgical treatment in patients with small renal cell carcinoma. Our results suggest that older patients with small renal cell carcinoma should be more closely followed after surgery than younger patients.
Key Words: kidney, carcinoma, renal cell, prognosis, age groups, mortality
Abbreviations and Acronyms: ECOG PS, Eastern Cooperative Oncology Group performance status, RCC, renal cell carcinoma
To access this article, please choose from the options below
Study received approval from the institutional review board at Asan Medical Center, Seoul, Republic of Korea.
Supported by Grant A062254 of the Korea Health 21 R
&D Project, Ministry of Health, Welfare and Family Affairs, Republic of Korea.
For other articles on a related topic see pages 721, 728 and 735.
PII: S0022-5347(09)00898-2
doi:10.1016/j.juro.2009.04.013
© 2009 American Urological Association. Published by Elsevier Inc. All rights reserved.
Refers to article:
- The bcl2 −938CC Genotype Has Poor Prognosis and Lower Survival in Renal Cancer , 18 June 2009
- CA9 Gene: Single Nucleotide Polymorphism Predicts Metastatic Renal Cell Carcinoma Prognosis , 18 June 2009
- Topoisomerase II α Status in Renal Medullary Carcinoma: Immuno-Expression and Gene Copy Alterations of a Potential Target of Therapy , 18 June 2009
